649 related articles for article (PubMed ID: 28642697)
21. Ginsenoside Rb1 protects dopaminergic neurons from inflammatory injury induced by intranigral lipopolysaccharide injection.
Li DW; Zhou FZ; Sun XC; Li SC; Yang JB; Sun HH; Wang AH
Neural Regen Res; 2019 Oct; 14(10):1814-1822. PubMed ID: 31169200
[TBL] [Abstract][Full Text] [Related]
22. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-124 regulates the expression of p62/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson's disease.
Yao L; Zhu Z; Wu J; Zhang Y; Zhang H; Sun X; Qian C; Wang B; Xie L; Zhang S; Lu G
FASEB J; 2019 Jul; 33(7):8648-8665. PubMed ID: 30995872
[TBL] [Abstract][Full Text] [Related]
24. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease.
Gao HM; Jiang J; Wilson B; Zhang W; Hong JS; Liu B
J Neurochem; 2002 Jun; 81(6):1285-97. PubMed ID: 12068076
[TBL] [Abstract][Full Text] [Related]
25. Fibroblast Growth Factor 21 Modulates Microglial Polarization That Attenuates Neurodegeneration in Mice and Cellular Models of Parkinson's Disease.
Yang C; Wang W; Deng P; Li C; Zhao L; Gao H
Front Aging Neurosci; 2021; 13():778527. PubMed ID: 35002679
[TBL] [Abstract][Full Text] [Related]
26. Chronic microglial activation and progressive dopaminergic neurotoxicity.
Block ML; Hong JS
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1127-32. PubMed ID: 17956294
[TBL] [Abstract][Full Text] [Related]
27. Protective Microglia and Their Regulation in Parkinson's Disease.
Le W; Wu J; Tang Y
Front Mol Neurosci; 2016; 9():89. PubMed ID: 27708561
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D Treatment Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in an Animal Model of Parkinson's Disease, Shifting M1 to M2 Microglia Responses.
Calvello R; Cianciulli A; Nicolardi G; De Nuccio F; Giannotti L; Salvatore R; Porro C; Trotta T; Panaro MA; Lofrumento DD
J Neuroimmune Pharmacol; 2017 Jun; 12(2):327-339. PubMed ID: 27987058
[TBL] [Abstract][Full Text] [Related]
29. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
30. Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
Sharma N; Nehru B
Mol Neurobiol; 2016 Jul; 53(5):3326-3337. PubMed ID: 26081143
[TBL] [Abstract][Full Text] [Related]
31. Ion channels on microglia: therapeutic targets for neuroprotection.
Skaper SD
CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):44-56. PubMed ID: 21143139
[TBL] [Abstract][Full Text] [Related]
32. Role of cytokines in inflammatory process in Parkinson's disease.
Sawada M; Imamura K; Nagatsu T
J Neural Transm Suppl; 2006; (70):373-81. PubMed ID: 17017556
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological Targeting of Microglial Activation: New Therapeutic Approach.
Liu CY; Wang X; Liu C; Zhang HL
Front Cell Neurosci; 2019; 13():514. PubMed ID: 31803024
[TBL] [Abstract][Full Text] [Related]
34. Taurine protects dopaminergic neurons in a mouse Parkinson's disease model through inhibition of microglial M1 polarization.
Che Y; Hou L; Sun F; Zhang C; Liu X; Piao F; Zhang D; Li H; Wang Q
Cell Death Dis; 2018 Apr; 9(4):435. PubMed ID: 29568078
[TBL] [Abstract][Full Text] [Related]
35. Recent progress in therapeutic strategies for microglia-mediated neuroinflammation in neuropathologies.
Gupta N; Shyamasundar S; Patnala R; Karthikeyan A; Arumugam TV; Ling EA; Dheen ST
Expert Opin Ther Targets; 2018 Sep; 22(9):765-781. PubMed ID: 30138572
[TBL] [Abstract][Full Text] [Related]
36. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
[TBL] [Abstract][Full Text] [Related]
37. TGF-β1 Neuroprotection via Inhibition of Microglial Activation in a Rat Model of Parkinson's Disease.
Chen X; Liu Z; Cao BB; Qiu YH; Peng YP
J Neuroimmune Pharmacol; 2017 Sep; 12(3):433-446. PubMed ID: 28429275
[TBL] [Abstract][Full Text] [Related]
38. Alternative microglial activation is associated with cessation of progressive dopamine neuron loss in mice systemically administered lipopolysaccharide.
Beier EE; Neal M; Alam G; Edler M; Wu LJ; Richardson JR
Neurobiol Dis; 2017 Dec; 108():115-127. PubMed ID: 28823928
[TBL] [Abstract][Full Text] [Related]
39. Galangin Reduces the Loss of Dopaminergic Neurons in an LPS-Evoked Model of Parkinson's Disease in Rats.
Chen G; Liu J; Jiang L; Ran X; He D; Li Y; Huang B; Wang W; Fu S
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29267220
[TBL] [Abstract][Full Text] [Related]
40. Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease.
Liu B
AAPS J; 2006 Sep; 8(3):E606-21. PubMed ID: 17025278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
